Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
A gene variation may affect tamoxifen's benefit in breast cancer
January 5th, 2006
One of the most commonly prescribed drugs for breast cancer, tamoxifen, may not be as effective for women who inherit a common genetic variation, according to researchers at the University of Michigan (U-M) and the Mayo Clinic. The genetic variation affects the level of a crucial enzyme that activates tamoxifen to fight breast cancer. The study, co-led by researcher James Rae, PhD, at the University of Michigan Comprehensive Cancer Center and Matthew Goetz, MD, an oncologist at the Mayo Clinic, tested the most common genetic variant responsible for lowering the CYP2D6 enzyme, and found that women with this genetic variant were almost twice as likely...
Source: Women's Health Weekly (2006-01-05)
|
